Mechanisms of Resistance to PD-1 and PD-L1 Blockade
Cancer immunotherapy utilizing blockade of the PD-1/PD-L1 checkpoint has revolutionized the treatment of a wide variety of malignancies, leading to durable therapeutic responses not typically seen with traditional cytotoxic anticancer agents. However, these therapies are ineffective in a significant...
Gespeichert in:
| Veröffentlicht in: | The cancer journal (Sudbury, Mass.) Mass.), 2018-01, Vol.24 (1), p.47-53 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 53 |
|---|---|
| container_issue | 1 |
| container_start_page | 47 |
| container_title | The cancer journal (Sudbury, Mass.) |
| container_volume | 24 |
| creator | Nowicki, Theodore S Hu-Lieskovan, Siwen Ribas, Antoni |
| description | Cancer immunotherapy utilizing blockade of the PD-1/PD-L1 checkpoint has revolutionized the treatment of a wide variety of malignancies, leading to durable therapeutic responses not typically seen with traditional cytotoxic anticancer agents. However, these therapies are ineffective in a significant percentage of patients, and some initial responders eventually develop resistance to these therapies with relapsed disease. The mechanisms leading to both primary and acquired resistance to PD-1/PD-L1 inhibition are varied and can be both multifactorial and overlapping in an individual patient. As the mechanisms of resistance to PD-1/PD-L1 blockade continue to be further characterized, new strategies are being developed to prevent or reverse resistance to therapy, leading to improved patient outcomes. |
| doi_str_mv | 10.1097/PPO.0000000000000303 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5785093</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1990852805</sourcerecordid><originalsourceid>FETCH-LOGICAL-c525t-85d1081cec49824d12e412d08486aad4eb5d7a2570dfb4bf513f734bbf28b1e63</originalsourceid><addsrcrecordid>eNpdkFtLw0AQhRdRbL38A5E8-pI6s5fs5kXQeoVKiyj4tmx2NzaaJjWbCv57U1pLdV5mYM45M3yEnCAMEFJ5PpmMB7BdDNgO6aPgEDOWvO4uZ6riFFH2yEEI7wAopYR90qMpS0BS1Sfs0dupqYowC1GdR08-FKE1lfVRW0eT6xgjU7nlMMLoqqzth3H-iOzlpgz-eN0PycvtzfPwPh6N7x6Gl6PYCiraWAmHoNB6y1NFuUPqOVIHiqvEGMd9Jpw0VEhwecazXCDLJeNZllOVoU_YIblY5c4X2cw766u2MaWeN8XMNN-6NoX-u6mKqX6rv7SQSkDKuoCzdUBTfy58aPWsCNaXpal8vQga0xRUxwhEJ-UrqW3qEBqfb84g6CVv3fHW_3l3ttPtFzemX8DsBx_Tebo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1990852805</pqid></control><display><type>article</type><title>Mechanisms of Resistance to PD-1 and PD-L1 Blockade</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Nowicki, Theodore S ; Hu-Lieskovan, Siwen ; Ribas, Antoni</creator><creatorcontrib>Nowicki, Theodore S ; Hu-Lieskovan, Siwen ; Ribas, Antoni</creatorcontrib><description>Cancer immunotherapy utilizing blockade of the PD-1/PD-L1 checkpoint has revolutionized the treatment of a wide variety of malignancies, leading to durable therapeutic responses not typically seen with traditional cytotoxic anticancer agents. However, these therapies are ineffective in a significant percentage of patients, and some initial responders eventually develop resistance to these therapies with relapsed disease. The mechanisms leading to both primary and acquired resistance to PD-1/PD-L1 inhibition are varied and can be both multifactorial and overlapping in an individual patient. As the mechanisms of resistance to PD-1/PD-L1 blockade continue to be further characterized, new strategies are being developed to prevent or reverse resistance to therapy, leading to improved patient outcomes.</description><identifier>ISSN: 1528-9117</identifier><identifier>EISSN: 1540-336X</identifier><identifier>DOI: 10.1097/PPO.0000000000000303</identifier><identifier>PMID: 29360728</identifier><language>eng</language><publisher>United States</publisher><subject>Animals ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; B7-H1 Antigen - antagonists & inhibitors ; Drug Resistance, Neoplasm - drug effects ; Humans ; Immunotherapy - methods ; Neoplasms - immunology ; Neoplasms - therapy ; Programmed Cell Death 1 Receptor - antagonists & inhibitors</subject><ispartof>The cancer journal (Sudbury, Mass.), 2018-01, Vol.24 (1), p.47-53</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c525t-85d1081cec49824d12e412d08486aad4eb5d7a2570dfb4bf513f734bbf28b1e63</citedby><cites>FETCH-LOGICAL-c525t-85d1081cec49824d12e412d08486aad4eb5d7a2570dfb4bf513f734bbf28b1e63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29360728$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nowicki, Theodore S</creatorcontrib><creatorcontrib>Hu-Lieskovan, Siwen</creatorcontrib><creatorcontrib>Ribas, Antoni</creatorcontrib><title>Mechanisms of Resistance to PD-1 and PD-L1 Blockade</title><title>The cancer journal (Sudbury, Mass.)</title><addtitle>Cancer J</addtitle><description>Cancer immunotherapy utilizing blockade of the PD-1/PD-L1 checkpoint has revolutionized the treatment of a wide variety of malignancies, leading to durable therapeutic responses not typically seen with traditional cytotoxic anticancer agents. However, these therapies are ineffective in a significant percentage of patients, and some initial responders eventually develop resistance to these therapies with relapsed disease. The mechanisms leading to both primary and acquired resistance to PD-1/PD-L1 inhibition are varied and can be both multifactorial and overlapping in an individual patient. As the mechanisms of resistance to PD-1/PD-L1 blockade continue to be further characterized, new strategies are being developed to prevent or reverse resistance to therapy, leading to improved patient outcomes.</description><subject>Animals</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>B7-H1 Antigen - antagonists & inhibitors</subject><subject>Drug Resistance, Neoplasm - drug effects</subject><subject>Humans</subject><subject>Immunotherapy - methods</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - therapy</subject><subject>Programmed Cell Death 1 Receptor - antagonists & inhibitors</subject><issn>1528-9117</issn><issn>1540-336X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkFtLw0AQhRdRbL38A5E8-pI6s5fs5kXQeoVKiyj4tmx2NzaaJjWbCv57U1pLdV5mYM45M3yEnCAMEFJ5PpmMB7BdDNgO6aPgEDOWvO4uZ6riFFH2yEEI7wAopYR90qMpS0BS1Sfs0dupqYowC1GdR08-FKE1lfVRW0eT6xgjU7nlMMLoqqzth3H-iOzlpgz-eN0PycvtzfPwPh6N7x6Gl6PYCiraWAmHoNB6y1NFuUPqOVIHiqvEGMd9Jpw0VEhwecazXCDLJeNZllOVoU_YIblY5c4X2cw766u2MaWeN8XMNN-6NoX-u6mKqX6rv7SQSkDKuoCzdUBTfy58aPWsCNaXpal8vQga0xRUxwhEJ-UrqW3qEBqfb84g6CVv3fHW_3l3ttPtFzemX8DsBx_Tebo</recordid><startdate>201801</startdate><enddate>201801</enddate><creator>Nowicki, Theodore S</creator><creator>Hu-Lieskovan, Siwen</creator><creator>Ribas, Antoni</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201801</creationdate><title>Mechanisms of Resistance to PD-1 and PD-L1 Blockade</title><author>Nowicki, Theodore S ; Hu-Lieskovan, Siwen ; Ribas, Antoni</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c525t-85d1081cec49824d12e412d08486aad4eb5d7a2570dfb4bf513f734bbf28b1e63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>B7-H1 Antigen - antagonists & inhibitors</topic><topic>Drug Resistance, Neoplasm - drug effects</topic><topic>Humans</topic><topic>Immunotherapy - methods</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - therapy</topic><topic>Programmed Cell Death 1 Receptor - antagonists & inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nowicki, Theodore S</creatorcontrib><creatorcontrib>Hu-Lieskovan, Siwen</creatorcontrib><creatorcontrib>Ribas, Antoni</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The cancer journal (Sudbury, Mass.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nowicki, Theodore S</au><au>Hu-Lieskovan, Siwen</au><au>Ribas, Antoni</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mechanisms of Resistance to PD-1 and PD-L1 Blockade</atitle><jtitle>The cancer journal (Sudbury, Mass.)</jtitle><addtitle>Cancer J</addtitle><date>2018-01</date><risdate>2018</risdate><volume>24</volume><issue>1</issue><spage>47</spage><epage>53</epage><pages>47-53</pages><issn>1528-9117</issn><eissn>1540-336X</eissn><abstract>Cancer immunotherapy utilizing blockade of the PD-1/PD-L1 checkpoint has revolutionized the treatment of a wide variety of malignancies, leading to durable therapeutic responses not typically seen with traditional cytotoxic anticancer agents. However, these therapies are ineffective in a significant percentage of patients, and some initial responders eventually develop resistance to these therapies with relapsed disease. The mechanisms leading to both primary and acquired resistance to PD-1/PD-L1 inhibition are varied and can be both multifactorial and overlapping in an individual patient. As the mechanisms of resistance to PD-1/PD-L1 blockade continue to be further characterized, new strategies are being developed to prevent or reverse resistance to therapy, leading to improved patient outcomes.</abstract><cop>United States</cop><pmid>29360728</pmid><doi>10.1097/PPO.0000000000000303</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1528-9117 |
| ispartof | The cancer journal (Sudbury, Mass.), 2018-01, Vol.24 (1), p.47-53 |
| issn | 1528-9117 1540-336X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5785093 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use B7-H1 Antigen - antagonists & inhibitors Drug Resistance, Neoplasm - drug effects Humans Immunotherapy - methods Neoplasms - immunology Neoplasms - therapy Programmed Cell Death 1 Receptor - antagonists & inhibitors |
| title | Mechanisms of Resistance to PD-1 and PD-L1 Blockade |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T02%3A31%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mechanisms%20of%20Resistance%20to%20PD-1%20and%20PD-L1%20Blockade&rft.jtitle=The%20cancer%20journal%20(Sudbury,%20Mass.)&rft.au=Nowicki,%20Theodore%20S&rft.date=2018-01&rft.volume=24&rft.issue=1&rft.spage=47&rft.epage=53&rft.pages=47-53&rft.issn=1528-9117&rft.eissn=1540-336X&rft_id=info:doi/10.1097/PPO.0000000000000303&rft_dat=%3Cproquest_pubme%3E1990852805%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1990852805&rft_id=info:pmid/29360728&rfr_iscdi=true |